In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses ROS+1 Fusions in NSCLC, including diagnosis, treatment and new exciting research coming down the pipeline. Her guests are: Dr. Lorenza Landi, Director of Clinical Trials Unit: Phase 1 and Precision Medicine at the National Cancer Institute Regina Elena in Rome. Dr. Landi has extensive experience and is interested in targeted therapy in lung cancer with a focus on ALK, HER-2/EGFR positive and ROS+1 lung cancer. Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology, at Henry Ford Cancer Institute in Detroit, Mich. Dr. Gadgeel is also part of the Lung Cancer steering committee for the Southwest Oncology Group and he is the Associate Editor of Clinical Lung Cancer and a reviewer for many journals.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related